Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2018 | Benefits of second generation TKIs for CML in the frontline

Giuseppe Saglio • 12 Sep 2018
SOHO 2018
Chronic Myeloid Leukemia Leukemia Imatinib

Giuseppe Saglio, MD, of the University of Turin, Turin, Italy, discusses the benefits of second generation TKIs for the frontline treatment of chronic myeloid leukemia (CML). These more potent inhibitors have reduced the rate of disease progression, being able to suppress certain clones that are resistant to imatinib. Dr Saglio highlights how these TKIs induce fast and deep responses; a very important property, even in low-risk patients. This interview was recorded at the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting held in Houston, TX.

More from Giuseppe Saglio

2:26
An insight into the aims of the Eurasian Hematology-Oncology Group
Giuseppe Saglio • 25 Oct 2022
3:20
The current standard of care in CML and insights into the use of first- and second-generation TKIs
Giuseppe Saglio • 25 Oct 2022
2:11
Addressing the issue of resistance to TKIs in CML
Giuseppe Saglio • 28 Oct 2022
3:35
TKI-related toxicities in CML & the importance of long-term monitoring
Giuseppe Saglio • 28 Sep 2022

Related Videos

3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
2:25
Optimizing haplo-SCT for the treatment of AML
Arnon Nagler • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals